159 related articles for article (PubMed ID: 16972276)
1. Increase in body weight after pramipexole treatment in Parkinson's disease.
Kumru H; Santamaria J; Valldeoriola F; Marti MJ; Tolosa E
Mov Disord; 2006 Nov; 21(11):1972-4. PubMed ID: 16972276
[TBL] [Abstract][Full Text] [Related]
2. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
[TBL] [Abstract][Full Text] [Related]
3. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
4. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease.
Lemke MR; Brecht HM; Koester J; Reichmann H
J Neurol Sci; 2006 Oct; 248(1-2):266-70. PubMed ID: 16814808
[TBL] [Abstract][Full Text] [Related]
5. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
Relja M; Klepac N
J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593
[TBL] [Abstract][Full Text] [Related]
6. The effect of pramipexole on depressive symptoms in Parkinson's disease.
Yasui N; Sekiguchi K; Hamaguchi H; Kanda F
Kobe J Med Sci; 2011 Feb; 56(5):E214-9. PubMed ID: 21937869
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
Möller JC; Oertel WH; Köster J; Pezzoli G; Provinciali L
Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
[TBL] [Abstract][Full Text] [Related]
8. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study.
Schapira AH; Albrecht S; Barone P; Comella CL; McDermott MP; Mizuno Y; Poewe W; Rascol O; Marek K
Mov Disord; 2010 Aug; 25(11):1627-32. PubMed ID: 20544810
[TBL] [Abstract][Full Text] [Related]
9. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease.
Künig G; Pogarell O; Möller JC; Delf M; Oertel WH
Clin Neuropharmacol; 1999; 22(5):301-5. PubMed ID: 10516884
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test.
Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G
Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263
[TBL] [Abstract][Full Text] [Related]
11. New dopamine agonist pramipexole improves parkinsonism and depression in Parkinson's disease.
Harada T; Ishizaki F; Horie N; Nitta Y; Yamada T; Sasaki T; Nagakane T; Yasumatsu Y; Nitta K; Katsuoka H
Hiroshima J Med Sci; 2011 Dec; 60(4):79-82. PubMed ID: 22389951
[TBL] [Abstract][Full Text] [Related]
12. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.
Bachmann CG; Zapf A; Brunner E; Trenkwalder C
Eur J Neurol; 2009 Aug; 16(8):895-901. PubMed ID: 19374662
[TBL] [Abstract][Full Text] [Related]
13. Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.
Perez Lloret S; Rascol O
Expert Opin Pharmacother; 2010 Sep; 11(13):2221-30. PubMed ID: 20670197
[TBL] [Abstract][Full Text] [Related]
14. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
[TBL] [Abstract][Full Text] [Related]
15. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
[TBL] [Abstract][Full Text] [Related]
16. Depressive illness in Parkinson's disease--indication of a more advanced and widespread neurodegenerative process?
Pålhagen SE; Carlsson M; Curman E; Wålinder J; Granérus AK
Acta Neurol Scand; 2008 May; 117(5):295-304. PubMed ID: 18279483
[TBL] [Abstract][Full Text] [Related]
17. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
Albrecht S; Buerger E
Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
[TBL] [Abstract][Full Text] [Related]
18. Pramipexole in the treatment of Parkinson's disease: new developments.
Möller JC; Oertel WH
Expert Rev Neurother; 2005 Sep; 5(5):581-6. PubMed ID: 16162081
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of body weight gain in patients with Parkinson's disease after subthalamic stimulation.
Montaurier C; Morio B; Bannier S; Derost P; Arnaud P; Brandolini-Bunlon M; Giraudet C; Boirie Y; Durif F
Brain; 2007 Jul; 130(Pt 7):1808-18. PubMed ID: 17535833
[TBL] [Abstract][Full Text] [Related]
20. Pramipexole for the treatment of early Parkinson's disease.
Perez-Lloret S; Rey MV; Ratti L; Rascol O
Expert Rev Neurother; 2011 Jul; 11(7):925-35. PubMed ID: 21721909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
